Drug intelligence / Profile preview

WD-iT1

Development stage: Preclinical
Lead developer: Wondercel Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

WD-iT1 is an induced regulatory T cell (iTreg) therapy being developed by Wondercel Therapeutics. It is designed to promote immune tolerance in patients undergoing solid organ transplantation, specifically for kidney, liver, and lung transplants. The therapy utilizes induced regulatory T cells to suppress the recipient's immune response against the donor organ, with the goal of preventing graft rejection and reducing the long-term requirement for systemic immunosuppressive drugs. WD-iT1 is currently in the preclinical stage of development.

Beyond the preview

Go deeper on WD-iT1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WD-iT1.

Explore the full profile